All News

RheumNow Podcast square

Generic Tofacitinib (6.26.2026)

Jack Cush, MD

Dr. Jack Cush reviews the news and journal articles from RheumNow.com. Updates on tofacitinib, CAR-T therapy and AI.

Read Article
guidelines.recommendations.jpg

2026 Guidelines for the Treatment of Axial Spondyloarthritis

ACR

New and updated clinical guidelines released today provide comprehensive, evidence-based recommendations for the management of axial spondyloarthritis (axSpA) for both adults and children.

Read Article
Biomarker,genes

Where are we with Biomarkers in Rheumatoid Arthritis?

Jack Cush, MD

Biomarker interest has grown considerably in the last 2 decades, owing to advances in genetics, imaging, protein, and multiomics. Despite these advances, biomarkers as the predictive holy grail of RA therapeutics and prognostication have not yet advanced beyond rheumatoid serologies and C-reactive protein (CRP).

Read Article
SPA.spectrum.jpg

Redefining axial spondyloarthritis

Jack Cush, MD

An editorial in Lancet Rheumatology calls for "..reframing axSpA as a systemic, autoimmune inflammatory disease with multiorgan involvement and substantial unmet need."

Read Article
back, LBP, spine, AS

JAMA Review on Low Back Pain

Jack Cush, MD

A comprehensive JAMA review synthesizes current evidence on the epidemiology, pathophysiology, clinical evaluation, and treatment of nonspecific low back pain, drawing on 108 publications identified from a PubMed search (2005–2026) and the most recent guidelines from the WHO, ACP, and NICE. While the primary audience is generalists, the review carries important implications for rheumatologists who regularly encounter patients with back pain in the context of inflammatory arthritis, axial spondyloarthritis, and other systemic diseases.

Read Article
CAR-T

CAR-T Cell Therapies at EULAR 2026

EurekAlert!

In an oral abstract presentation on Wednesday 3rd June, Fredrik Albach presented results for mivocabtagene autoleucel – an autologous, fully human CD19-directed CAR-T cell therapy – from Phase 1 of the prospective, open-label COMPARE trial in six patients with anti-citrullin

Read Article
Eular stage

Late-Breaking Studies at EULAR 2026

MedPage Today

Late-breaking abstracts presented at the European Alliance of Associations for Rheumatology's (EULAR) annual meeting, held here last week, addressed a wide range of clinical conc

Read Article
RheumNow Podcast square

EULAR 2026 Rheumatology RoundUp

Jack Cush, MD

It’s time for Rheumatology RoundUp from EULAR 2026 from London, UK. Drs. Artie Kavanaugh and Jack Cush review their choice presentations from the meeting, offering their perspectives on impact and applicability.

Read Article
Breckenridge Pharmaceutical received FDA approval for their generic version of tofacitinib on 6/4/26. 5 mg and 10 mg tablets are now available in the U.S. market, for both adult and pediatric use. Tofacitinib Tablets are manufactured in Martorelles, Spain. https://t.co/oAh0KQSFgs https://t.co/fNxEm31MAI

Links:

Dr. John Cush RheumNow ( View Tweet)
How many CAR-T’s do we need to test drive? There were 93 abstracts with CAR-T in title at #EULAR2026! Additionally, there was an excellent review (WIN) by Dr. Hector Chinoy. We know lots but have more questions. https://t.co/dGpfffaubX https://t.co/3MS1ZjQExj

Links:

Dr. John Cush RheumNow ( View Tweet)
Long-term Cancer Risk with Targeted Therapy in SpA Dr. Antoni Chan reports on abstract OP0238 presented at EULAR 2026 in London https://t.co/f67SvKI6Vk https://t.co/fPp2H0aMoK

Links:

Dr. John Cush RheumNow ( View Tweet)
A provacative OPINION piece in The Hill asks, is "China is quietly taking control of US medicine..." Should the US & FDA facilitating, ignorning or opposing Chinas influence? Issues of transparency, manufacturing, global supply chain, outsourcing early phase RCTs, etc. https://t.co/4vveTR8UK8
Dr. John Cush RheumNow ( View Tweet)
SLE Pipeline of New Therapies Dr. Andrea Fava, EULAR 2026 in London. https://t.co/GwntaPwzWr https://t.co/prFnaSKuqF

Links:

Dr. John Cush RheumNow ( View Tweet)
RheumNow’s expanded coverage of the #EULAR2026 Annual Meeting is sponsored by Bristol Myers Squibb and UCB. RheumNow and its faculty independently select all coverage content.

Dr. John Cush RheumNow ( View Tweet)

All content is independently chosen and produced by the RheumNow faculty. Our expanded #EULAR2026 coverage is made possible by support from Bristol Myers Squibb and UCB.

Dr. John Cush RheumNow ( View Tweet)

RheumNow’s expanded coverage of #EULAR2026 annual meeting is sponsored by Bristol Myers Squibb and UCB. RheumNow and its faculty independently select all coverage content.

Dr. John Cush RheumNow ( View Tweet)

JAK Safety Debate Continues: Stronger VTE signal, less clear cancer signal Few topics in rheumatology have reshaped prescribing behaviour as dramatically as the safety concerns surrounding JAK inhibitors following ORAL Surveillance and the subsequent FDA and EMA warnings. https://t.co/mvTRRL7srA
Dr. John Cush RheumNow ( View Tweet)
Not all #RA pts respond equally to advanced therapy. 10-variable risk model >18k US pts: low baseline disease activity, fewer comorbidities, and no prior biologics 5x more likely to achieve remission at 1yr (34% vs 7%). RWD for precision care @RheumNow #EULAR2026 POS0257

Jiha Lee JihaRheum ( View Tweet)

Our expanded #EULAR2026 coverage is made possible by support from Bristol Myers Squibb and UCB. All content is independently chosen and produced by the RheumNow faculty.

Dr. John Cush RheumNow ( View Tweet)

Looking forward to CAR T cell therapy trials in #SSc Phase 2 and 3 studies presented at #HOT session by Pr Oliver Distler #CAR_T #EULAR2026 @RheumNow https://t.co/bmXZpF2wKg

Links:

Nelly ZIADE 🍀 Nellziade ( View Tweet)
How well do you know this week's rheumatology news?
Take the rheumIQ quiz
Take the RheumIQ Quiz

×